Research Topics
| Kathleen E SquiresSummaryAffiliation: Thomas Jefferson University Country: USA Publications
| Collaborators
|
Detail Information
Publications
ARIES 144 week results: durable virologic suppression in HIV-infected patients simplified to unboosted atazanavir/abacavir/lamivudineKathleen E Squires
Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA
HIV Clin Trials 13:233-44. 2012..Non-inferiority of the unboosted regimen was demonstrated at week 84. In this optional extension phase, virologic suppression and adverse events were assessed through week 144...
Gender-sensitive reporting in medical researchShirin Heidari
International AIDS Society, Geneva, Switzerland
J Int AIDS Soc 15:11. 2012..Journal editors are also promoters of ethical research and adequate standards of reporting, and requirements for inclusion of gender analyses should be integrated into editorial policies as a matter of urgency...- Safety and efficacy of a 36-week induction regimen of abacavir/lamivudine and ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires
Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
HIV Clin Trials 11:69-79. 2010..The ARIES study assessed safety and efficacy of an induction regimen with atazanavir/ritonavir (ATV/RTV) + abacavir/lamivudine (ABC/3TC) followed by simplification to ATV + ABC/3TC in antiretroviral-naïve patients... 
Gender differences in the diagnosis and treatment of HIVKathleen E Squires
Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA 19107, USA
Gend Med 4:294-307. 2007..Timing and choice of treatment are affected by the pharmacokinetics of antiretroviral drugs and the long-term complications of treatment, both of which may be different for men and women with HIV infection...- Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE studyKathleen E Squires
Jefferson Medical College of Thomas Jefferson University, 211 South 9th Street, Philadelphia, PA 19107, USA
J Antimicrob Chemother 66:363-70. 2011..The trial is registered with ClinicalTrials.gov, number NCT00272779... - Health needs of HIV-infected women in the United States: insights from the women living positive surveyKathleen E Squires
Jefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS Patient Care STDS 25:279-85. 2011..These data highlight a need for U.S. health care providers to incorporate discussion of gender-specific issues, including preconception and reproductive counseling, into management strategies for HIV-infected women... - Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patientsKathleen E Squires
Division of Infectious Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
AIDS 24:2019-27. 2010.... - Association between abacavir exposure and increased risk for cardiovascular disease in patients with human immunodeficiency virusJason J Schafer
Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, Pennsylvania 19107 5233, USA
Pharmacotherapy 30:1072-83. 2010..Studies are also necessary to definitively identify the contributions of both HIV infection and individual antiretroviral agents on the development of cardiovascular disease... - A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimenScott M Hammer
Division of Infectious Diseases, Columbia University, New York, New York 10032, USA
HIV Clin Trials 11:312-24. 2010..The objective of AIDS Clinical Trials Group Study 372A was to determine whether the intensification strategy of adding abacavir to an effective indinavir-dual nucleoside regimen would delay the time to virologic failure... - Integrase inhibitors: a novel class of antiretroviral agentsJason J Schafer
Jefferson School of Pharmacy, Thomas Jefferson University, Philadelphia, PA 19107, USA
Ann Pharmacother 44:145-56. 2010..To review the pharmacology, efficacy, safety, and resistance profiles of the integrase inhibitors raltegravir and elvitegravir... - Prevalence of obstructive lung disease in HIV population: a cross sectional studyAmyn Hirani
Division of Pulmonary and Critical Care Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Respir Med 105:1655-61. 2011..Observational studies have suggested an association between HIV infection and emphysema... - Women and HIV: a population at riskKathleen E Squires
Division of Infectious Diseases, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Res Initiat Treat Action 12:18-20. 2007 - Gender-specific considerations in the antiretroviral management of HIV-infected womenRebecca A Clark
HIV Outpatient Program, New Orleans, LA 70112, USA
Expert Rev Anti Infect Ther 3:213-27. 2005..Further investigation into gender-related issues, including sex-associated antiretroviral toxicities, unique pharmacokinetic profiles and optimal antiretroviral management during pregnancy is needed... - Once-daily antiretroviral therapies for HIV infection: Consensus Statement of an Advisory Committee of the International Association of Physicians in AIDS CareCalvin Cohen
CRI New England, 23 Miner Street, Boston, Massachusetts 02215-3318, USA
J Int Assoc Physicians AIDS Care (Chic Ill) 1:141-5. 2002..The opinions expressed in this Consensus Statement represent only those of the Advisory Committee... - Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trialRoy M Gulick
Cornell HIV Clinical Trials Unit, Division of International Medicine and Infectious Diseases, Weill Medical College of Cornell University, New York, NY, USA
JAMA 296:769-81. 2006..Three-drug antiretroviral regimens are standard of care for initial treatment of human immunodeficiency virus 1 (HIV-1) infection, but a 4-drug regimen could improve antiretroviral activity and be more effective than a 3-drug regimen... - Treating HIV infection and AIDS in womenKathleen E Squires
University of Southern California (USC) Keck School of Medicine, Los Angeles, California, USA
AIDS Read 13:228-34, 239-40. 2003 - Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppressionRoy M Gulick
Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
AIDS 21:813-23. 2007..To compare a quadruple-nucleoside with an efavirenz-containing regimen for treatment of HIV-1 infection... - Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248)Mary A Vogler
New York University Medical Center, New York, NY 10016, USA
J Acquir Immune Defic Syndr 36:576-87. 2004..Approaches to preserve or enhance immune function in HIV-1 infection are needed... - The costs of HIV antiretroviral therapy adherence programs and impact on health care utilizationStephanie L Sansom
US Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
AIDS Patient Care STDS 22:131-8. 2008..IACM was associated with a significant decrease in hospital days compared to SOC and was cost saving when program costs were compared to savings in health care utilization... - Factors influencing the acceptance of changes in antiretroviral therapy among HIV-1-infected patientsRafael E Campo
University of Miami School of Medicine, Miami, Florida 33136, USA
AIDS Patient Care STDS 21:329-38. 2007..ART acceptance rates among Hispanic patients were lower... - Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166sDaniel R Kuritzkes
Section of Retroviral Therapeutics, Brigham and Women s Hospital, Cambridge, MA 02139, USA
J Infect Dis 195:1169-76. 2007..We sought to compare clearance rates of plasma human immunodeficiency virus type 1 (HIV-1) RNA in men and women starting triple-nucleoside-based versus efavirenz (EFV)-based regimens... - Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patientsGail Skowron
Roger Williams Medical Center, Providence, Rhode Island 02908, USA
J Infect Dis 186:1028-33. 2002.... - Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activitySharon A Riddler
University of Pittsburgh, Pennsylvania, USA
Antimicrob Agents Chemother 46:3877-82. 2002..The combination of IDV and NFV was generally well tolerated and resulted in sustained virologic suppression with 45% of the subjects having an HIV-1 RNA level in plasma of <400 copies/ml at week 72 (intent-to-treat)... - A prospective study of genital herpes simplex virus type 2 infection in human immunodeficiency virus type 1 (HIV-1)-seropositive women: correlations with CD4 cell count and plasma HIV-1 RNA levelPatty W Wright
Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0006, USA
Clin Infect Dis 36:207-11. 2003..Positive HSV-2 culture results occurred more frequently for samples obtained from patients with higher plasma HIV-1 RNA levels (P=.019) and lower CD4 cell counts (P<.001)... - Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative womenRaphael P Viscidi
Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
J Infect Dis 187:194-205. 2003..Despite the higher prevalence of HPV infection in this group, most HIV-positive women are able to control HPV-16 replication at the cervix, and reactivation, if it occurs, is not very common... - Current management challenges in HIV: antiretroviral resistanceDaniel R Kuritzkes
Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts, USA
AIDS Read 13:133-5, 138-42. 2003..However, there is a need for additional trials to better define the role resistance testing may play in developing management approaches to mitigate or minimize emergence of resistant HIV... - Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjectsRobert Dicenzo
University at Buffalo, Buffalo, New York, USA
Antimicrob Agents Chemother 47:1929-35. 2003..Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h... - Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infectionRoy M Gulick
Weill Medical College of Cornell University, New York, USA
N Engl J Med 350:1850-61. 2004.... - Incidence and risk factors for sexually transmitted infections among women in an Alabama HIV clinicCheryl-Ann Monteiro
Department of Medicine, The University of Alabama at Birmingham, Alabama 35294, USA
AIDS Res Hum Retroviruses 20:577-83. 2004..99 (1.28, 3.08), and a higher CD4+ T cell count, RR = 1.15 (1.0028, 1.3115) for 100 cells. Interventions to prevent curable STI in HIV-infected women are warranted in primary care settings... - Editorial comment: HIV-infected women require a range of specialized servicesKathleen E Squires
AIDS Read 15:426. 2005 - Editorial comment: women and HIV--a population at riskKathleen E Squires
AIDS Read 16:374-5. 2006 - Comparative analysis of commercial assays for the detection and quantification of Human Immunodeficiency Virus Type 1 (HIV-1) RNA in plasma from patients infected with HIV-1 subtype CCraig J Hoesley
Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, 35294, USA
Clin Infect Dis 35:323-5. 2002..Each assay detected plasma HIV-1 RNA, but they do not all measure statistically similar quantities of plasma HIV-1 RNA...